COMP <GO>
USPH vs INNV // EV/EBITDA & P/E VALUATION
U.S. Physical Therapy Inc. (NYSE) VS. InnovAge Holding Corp. (NASDAQ) • 15-METRIC TALLY: USPH 10
— INNV 1
■ METRIC PARITY
LAST: $86.57 (+1.47%) • MKT CAP: $1.29B
valuation
16.3x
LAST: $9.24 (+1.54%) • MKT CAP: $1.26B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USPH VS. INNV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USPH | INNV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.20% | 18.00% | +1.20 | USPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | -10.20% | +21.70 | USPH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 16.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.81% | 2.11% | +3.70 | USPH | /fcf-yield <GO> |
| Operating Margin | 11.10% | -3.50% | +14.60 | USPH | /operating-margins <GO> |
| Net Profit Margin | 5.10% | -3.60% | +8.70 | USPH | /net-margins <GO> |
| Revenue Growth (YoY) | 16.30% | 11.80% | +4.50 | USPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.12% | 0.00% | +2.12 | USPH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.94 | 4.47 | -1.53 | INNV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | USPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 45.7 | +6.53 | USPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29B | $1.26B | $31.0M | USPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USPH REV | INNV REV | USPH GROSS % | INNV GROSS % | USPH FCF | INNV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $781.0M | $853.7M | 19.2% | 18.0% | $75.1M | $26.6M |
| FY 2024 | $671.3M | $763.9M | 18.5% | 17.3% | $74.9M | -$44.8M |
| FY 2023 | $604.8M | $688.1M | — | — | $82.0M | $20.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USPH // BETA —
INNV // BETA —